



Date: 27th May, 2025

To,
Department of Corporate Services
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400 001

Scrip Code: 531569

Sub: Revised Press Release on Audited Financial Results (Standalone and Consolidated) for the Quarter and Year ended March 31, 2025.

Dear Sir/ Madam,

Pursuant to Regulation 30 of Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015 please find enclosed the press release on Audited Financial Results (Standalone and Consolidated) for the Quarter and Year ended March 31, 2025.

Kindly take the above information on your records.

Thanking You,
Yours Faithfully,

For Sanjivani Paranteral Limited

Ravikumar Bogam
Company Secretary Cum Compliance Officer

Press Release

Sanjivani Paranteral Limited reported its results for the quarter & year ended 31st March 2025

Mumbai, 27th May 2025: Sanjivani Paranteral Ltd (BSE: 531569) is a pharmaceutical company headquartered in Mumbai and four manufacturing plants at Navi Mumbai, Dehradun, Pimpri & Czech Republic, specializing in the manufacturing and distribution of high-quality parenteral and oral solid products. We cater major therapeutic/product areas encompassing CNS, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

Commenting on the results, Mr. Ashwani Khemka Chairman & Managing Director, Sanjivani Paranteral Ltd. said, “We are pleased with the performance this quarter, which reflects our continued focus on operational efficiency, quality manufacturing, and strategic market expansion. Our efforts to strengthen the core business and explore growth opportunities have yielded encouraging results. As we move forward, we remain committed to innovation, regulatory compliance, and delivering value to our stakeholders.”

Financial Summary:

Q4 FY25:

- Revenue from operation grew 41.3% YoY to INR 181.8 mn.
- EBITDA margin stood at 16.8% (down 42bps YoY).
- Profit After Tax (PAT) stood at 21.9 mn. (up 74.4% YoY).

Particulars (Rs. in mn.)	Q4FY25	Q4FY24	Q3FY25	FY25	FY24
Total Income	186.1	129.2	176.6	713.1	549.3
Gross Profit	92.1	79.7	77.3	308.3	264.4
Gross Margin (%)	50.7%	61.9%	44.6%	44.0%	48.6%
EBITDA incl. other income	30.5	22.1	28.6	115.7	87.6
EBITDA Margin (%)	16.8%	17.2%	16.5%	16.5%	16.1%
PBT	26.6	18.8	25.1	103.6	75.7
PBT Margin %	14.3%	14.6%	14.2%	14.5%	13.8%
PAT	21.9	12.6	19.0	81.0	61.7
PAT Margin (%)	11.8%	9.7%	10.7%	11.4%	11.2%
EPS (in INR)	1.84	1.08	1.62	6.89	5.28

Segment-wise Performance:

- **Injectables:** Revenue grew 16.1% YoY to Rs. 130.8mn.
- **Oral:** Revenue grew 11.4% YoY to INR 49.1mn.
- **Nutraceuticals:** Revenue grew 4.1% YoY to INR 1.9mn.

Market-Wise Performance:

- Exports (incl. Exports incentives) constitute 72.5% of total revenue while domestic constitutes 27.5%.
- Core markets of CIS (including Russia), Middle East & Africa and Latin America, accounted for 72.5% to INR 131.9mn.

FY25:

- Revenue from operation grew 28.8% YoY to INR 701.0 mn.
- EBITDA margin stood at 16.5% (up 41bps YoY).
- Profit After Tax (PAT) grew 31.4% YoY to INR 81.0 mn.

Segment-wise Performance:

- **Injectables:** Revenue grew 8.3% YoY to Rs. 411.8mn.
- **Oral:** Revenue grew 62.9% YoY to INR 259.7mn.
- **Nutraceuticals:** Revenue grew 564% YoY to INR 29.5mn.

Market-Wise Performance:

- Exports (incl. Exports incentives) constitute 81.5% of total revenue while domestic constitutes 18.5%.
- Core markets of CIS (including Russia), Middle East & Africa and Latin America, accounted for 81.5% of FY25 revenue to Rs 571.6 mn.

Pritesh Jain

Sanjivani Paranteral

Chief Financial Officer

pritesh.jain@sanjivani.co.in**DISCLAIMER:**

Certain statements that are made in the Press Release may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Sanjivani Paranteral Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.